Standard molecular biology typically seeks stronger promoters to increase RNA transcription rates, but slowing decay accomplishes the same endpoint. Because circular RNA lacks vulnerable free ends, it resists typical intracellular turnover machinery and accumulates continuously to achieve far higher steady-state expression levels than linear mRNA.
AAV gene therapies frequently require dangerously high doses because baseline expression is low. Boosting expression over 200-fold using circular RNA cassettes allows developers to cut viral dosing proportionally, dramatically reducing manufacturing costs, resolving capsid-related toxicities, and potentially reviving assets abandoned due to insufficient potency.
In vivo CAR applications face a difficult trade-off between ultra-short LNP-mRNA expression and permanently integrating lentiviruses that carry oncogenic risks. Circular RNA provides a transient three-to-six-month expression window that is durable enough to clear solid and liquid tumors while remaining completely re-dosable and reversible.
Optimizing non-viral gene delivery requires screening across delivery systems, DNA payload conformations, and expression formats simultaneously. Switching from standard double-stranded DNA to single-stranded formats encoding circular RNA can generate immune-quiet vectors that exhibit high stability and prolonged in vivo expression without requiring viral capsids.
Single-asset clinical biotechs demand massive funding rounds and expose investors to binary clinical readouts with sparse intermediate data flow. Operating a well-funded preclinical platform with multiple distinct programs mitigates binary downside, sustains steady milestone cadence, and eliminates the pressure to disclose exploratory early-stage negative data.
